A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT ID: NCT00808288
Last Updated: 2019-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
405 participants
INTERVENTIONAL
2010-03-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
NCT00783406
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01054885
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
NCT01033487
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01053988
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
NCT00468975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-00610355
PF-00610355
oral, inhaled, dry powder, 600ug, OD
PF- 00610355
PF - 00610355
oral, inhaled, dry powder, 300ug, OD
PF - 00610355
PF- 00610355
oral, inhaled, dry powder, 100ug, OD
Placebo
Placebo
oral, inhaled, dry powder, placebo, OD
Salmeterol
Salmeterol
salmeterol, 50ug, BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-00610355
oral, inhaled, dry powder, 600ug, OD
PF - 00610355
oral, inhaled, dry powder, 300ug, OD
PF- 00610355
oral, inhaled, dry powder, 100ug, OD
Placebo
oral, inhaled, dry powder, placebo, OD
Salmeterol
salmeterol, 50ug, BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of moderate COPD for a minimum of 6 months.
* Stable disease for at least 1 month prior to screening
Exclusion Criteria
* History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Fairhope, Alabama, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Spring Valley, California, United States
Pfizer Investigational Site
Wheat Ridge, Colorado, United States
Pfizer Investigational Site
Daytona Beach, Florida, United States
Pfizer Investigational Site
Ormond Beach, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Trinity, Florida, United States
Pfizer Investigational Site
Austell, Georgia, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Fridley, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Rochester, Minnesota, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Lincoln, Rhode Island, United States
Pfizer Investigational Site
Pawtucket, Rhode Island, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Columbia, South Carolina, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Morgantown, West Virginia, United States
Pfizer Investigational Site
Rosario, Santa Fe Province, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Rousse, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Stara Zagora, , Bulgaria
Pfizer Investigational Site
Troyan Municipality, , Bulgaria
Pfizer Investigational Site
Zagreb, , Croatia
Pfizer Investigational Site
Kutná Hora, , Czechia
Pfizer Investigational Site
Liberec, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Tábor, , Czechia
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Kassel, , Germany
Pfizer Investigational Site
Lübeck, , Germany
Pfizer Investigational Site
Schwerin, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Debrecen, , Hungary
Pfizer Investigational Site
Szeged, , Hungary
Pfizer Investigational Site
Szombathely, , Hungary
Pfizer Investigational Site
Törökbálint, , Hungary
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Sopot, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Wejherowo, , Poland
Pfizer Investigational Site
Bojnice, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Liptovský Hrádok, , Slovakia
Pfizer Investigational Site
Nové Zámky, , Slovakia
Pfizer Investigational Site
Poprad, , Slovakia
Pfizer Investigational Site
Spišská Nová Ves, , Slovakia
Pfizer Investigational Site
Bellville, Cape Town, South Africa
Pfizer Investigational Site
Tygerberg, Cape Town, South Africa
Pfizer Investigational Site
Bloemfontein, Free State, South Africa
Pfizer Investigational Site
Bloemfontein, , South Africa
Pfizer Investigational Site
Gatesville, Cape Town, , South Africa
Pfizer Investigational Site
Salt, Girona, Spain
Pfizer Investigational Site
Pozuelo de Alarcón, Madrid, Spain
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7881013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.